Search
Jun 26
Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program
Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest
Aug 4, 2023
Wave Life Sciences demonstrates high throughput oligonucleotide synthesis and talks RNA editing
Paul Bolno shows us how Wave discovers and develops its own oligonucleotides as Wave prepares to enter the clinic with RNA editing.